Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $3.1 million.

  • Stoke Therapeutics' Change in Accured Expenses rose 751.67% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 6169.17%. This contributed to the annual value of $3.1 million for FY2024, which is 196.26% up from last year.
  • Stoke Therapeutics' Change in Accured Expenses amounted to $3.1 million in FY2024, which was up 196.26% from -$3.2 million recorded in FY2023.
  • Stoke Therapeutics' Change in Accured Expenses' 5-year high stood at $5.2 million during FY2020, with a 5-year trough of -$3.5 million in FY2022.
  • Over the past 3 years, Stoke Therapeutics' median Change in Accured Expenses value was -$3.2 million (recorded in 2023), while the average stood at -$1.2 million.
  • Per our database at Business Quant, Stoke Therapeutics' Change in Accured Expenses soared by 483.95% in 2020 and then slumped by 221.85% in 2022.
  • Over the past 5 years, Stoke Therapeutics' Change in Accured Expenses (Yearly) stood at $5.2 million in 2020, then plummeted by 44.32% to $2.9 million in 2021, then slumped by 221.85% to -$3.5 million in 2022, then climbed by 9.12% to -$3.2 million in 2023, then soared by 196.26% to $3.1 million in 2024.